Intercure (TA:INCR) — Market Cap & Net Worth
Market Cap & Net Worth: Intercure (INCR)
Intercure (TA:INCR) has a market capitalization of $171.47 Million (ILA63.96 Billion) as of September 20, 2026. Listed on the TA stock exchange, this Israel-based company holds position #17238 globally and #209 in its home market, demonstrating a -2.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intercure's stock price ILA1600.00 by its total outstanding shares 59228556 (59.23 Million). Also see INCR total asset value for a full breakdown of the balance sheet.
Intercure Market Cap History: 2015 to 2026
Intercure's market capitalization history from 2015 to 2026. Data shows growth from $24.73 Million to $254.06 Million (23.90% CAGR). Also see INCR operating cash flow for how efficiently the company converts equity into cash flow.
Intercure Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intercure's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Intercure stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.19x
Intercure's market cap is 0.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $262.04 Million | $8.93 Million | -$5.89 Million | 29.36x | N/A |
| 2020 | $259.64 Million | $65.03 Million | -$37.23 Million | 3.99x | N/A |
| 2021 | $329.01 Million | $219.68 Million | $4.69 Million | 1.50x | 70.15x |
| 2022 | $191.82 Million | $388.68 Million | $44.82 Million | 0.49x | 4.28x |
| 2023 | $73.44 Million | $355.55 Million | -$61.96 Million | 0.21x | N/A |
| 2024 | $94.48 Million | $238.84 Million | -$67.80 Million | 0.40x | N/A |
| 2025 | $51.29 Million | $270.20 Million | -$35.71 Million | 0.19x | N/A |
Competitor Companies of INCR by Market Capitalization
Companies near Intercure in the global market cap rankings as of September 20, 2026. Review how tangible is Intercure's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Intercure by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #612 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #612 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Intercure Historical Marketcap From 2015 to 2026
Between 2015 and today, Intercure's market cap moved from $24.73 Million to $ 254.06 Million, with a yearly change of 23.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA254.06 Million | +395.36% |
| 2025 | ILA51.29 Million | -45.71% |
| 2024 | ILA94.48 Million | +28.65% |
| 2023 | ILA73.44 Million | -61.71% |
| 2022 | ILA191.82 Million | -41.70% |
| 2021 | ILA329.01 Million | +26.72% |
| 2020 | ILA259.64 Million | -0.92% |
| 2019 | ILA262.04 Million | -26.70% |
| 2018 | ILA357.49 Million | +1267.57% |
| 2017 | ILA26.14 Million | -33.21% |
| 2016 | ILA39.14 Million | +58.29% |
| 2015 | ILA24.73 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Intercure was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $171.47 Million USD |
| MoneyControl | $171.47 Million USD |
| MarketWatch | $171.47 Million USD |
| marketcap.company | $171.47 Million USD |
| Reuters | $171.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in… Read more